Concorde Asset Management, LLC Fulgent Genetics, Inc. Transaction History

Concorde Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$49.85 - $96.11 $515,598 - $994,065	-10,343 Closed	0 $0
Q4 2021 Feb 02, 2022	BUY	$77.3 - $105.0 $8,812 - $11,970	114 Added 1.11%	10,343 $1.04 Million
Q3 2021 Oct 21, 2021	BUY	$74.87 - $110.87 $596,938 - $883,966	7,973 Added 353.41%	10,229 $920,000
Q2 2021 Jul 20, 2021	SELL	$66.8 - $100.45 $118,970 - $178,901	-1,781 Reduced 44.12%	2,256 $208,000
Q1 2021 Apr 27, 2021	SELL	$59.3 - $183.85 $1.45 Million - $4.5 Million	-24,472 Reduced 85.84%	4,037 $390,000
Q4 2020 Jan 29, 2021	BUY	$31.01 - $52.1 $219,736 - $369,180	7,086 Added 33.08%	28,509 $1.49 Million
Q3 2020 Oct 23, 2020	BUY	$15.89 - $50.51 $340,411 - $1.08 Million	21,423 New	21,423 $858,000

201

16.1M

2.04M

14K

Ticker FLGT
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 30,265,800
Market Cap $609M
Description
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...

Get notified when there are updates to the investment portfolio of Concorde Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Concorde Asset Management, LLC with notifications on news.